Journal of Clinical Oncology, Vol 25, No 17 (June 10), 2007: pp. 2369-2376
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.07.8170
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
Lee S. Rosen,
Razelle Kurzrock,
Marilyn Mulay,
Andy Van Vugt,
Michelle Purdom,
Chaan Ng,
Jeffrey Silverman,
Antonis Koutsoukos,
Yu-Nien Sun,
Michael B. Bass,
Ren Y. Xu,
Anthony Polverino,
Jeffrey S. Wiezorek,
David D. Chang,
Robert Benjamin,
Roy S. Herbst
From the Premiere Oncology, Santa Monica; Landmark Imaging, Los Angeles; Amgen Inc, Thousand Oaks, CA; and the Division of Cancer Medicine Phase 1 Program, Department of Radiology, Department of Sarcoma, and Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Address reprint requests to Roy S. Herbst, MD, PhD, The University of Texas M.D. Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030; e-mail: rherbst{at}mdanderson.org
Purpose AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell factor receptor. This phase I, dose-finding study evaluated the safety, pharmacokinetics, and pharmacodynamics of AMG 706 in patients with refractory advanced solid tumors.
Patients and Methods AMG 706 was administered at escalating doses of 50 to 175 mg once daily or 25 mg bid for the first 21 days of a 28-day cycle. The 125-mg once-daily dose was also administered continuously. The maximum-tolerated dose (MTD), safety, pharmacokinetics, tumor response, and serum levels of proangiogenic markers were determined.
Results Seventy-one patients received AMG 706. The MTD was 125 mg once daily administered continuously. The most frequent adverse events were fatigue (55%), diarrhea (51%), nausea (44%), and hypertension (42%). Plasma AMG 706 concentrations increased in a dose-proportional manner with no accumulation after multiple doses. Five patients (7%) had a partial response, 35 patients (49%) had stable disease (at least through day 50), and 31 patients (44%) had progressive disease. Changes in tumor size correlated significantly with an increase in placental growth factor (P = .003) and a decrease in soluble kinase domain receptor (P = .001).
Conclusion In this study of patients with advanced refractory solid tumors, AMG 706 was well tolerated and displayed favorable pharmacokinetics and evidence of antitumor activity. Additional studies of AMG 706 as monotherapy and in combination with various agents are ongoing.
Supported by Amgen Inc and the Cancer Center Support Core Grant No. 5P30 CA016672-30 (R.S.H.).
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. M. Tsimberidou, C. Vaklavas, S. Wen, D. Hong, J. Wheler, C. Ng, A. Naing, S. Tse, N. Busaidy, M. Markman, et al.
Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience
J. Clin. Endocrinol. Metab.,
November 1, 2009;
94(11):
4423 - 4432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-I. Wong, T.-S. Koh, R. Soo, S. Hartono, C.-H. Thng, E. McKeegan, W.-P. Yong, C.-S. Chen, S.-C. Lee, J. Wong, et al.
Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
J. Clin. Oncol.,
October 1, 2009;
27(28):
4718 - 4726.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Schlumberger, R. Elisei, L. Bastholt, L. J. Wirth, R. G. Martins, L. D. Locati, B. Jarzab, F. Pacini, C. Daumerie, J.-P. Droz, et al.
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
J. Clin. Oncol.,
August 10, 2009;
27(23):
3794 - 3801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, M. Kuchimanchi, D. Hickman, L. Poppe, M. Hayashi, Y. Zhou, R. Subramanian, G. Kumar, and S. Surapaneni
In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans
Drug Metab. Dispos.,
July 1, 2009;
37(7):
1378 - 1394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bhargava
VEGF kinase inhibitors: how do they cause hypertension?
Am J Physiol Regulatory Integrative Comp Physiol,
July 1, 2009;
297(1):
R1 - R5.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Sherman
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
J. Clin. Endocrinol. Metab.,
May 1, 2009;
94(5):
1493 - 1499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Eur. J. Endocrinol.,
March 1, 2009;
160(3):
331 - 336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Coxon, T. Bush, D. Saffran, S. Kaufman, B. Belmontes, K. Rex, P. Hughes, S. Caenepeel, J. B. Rottman, A. Tasker, et al.
Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors
Clin. Cancer Res.,
January 1, 2009;
15(1):
110 - 118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al.
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
N. Engl. J. Med.,
July 3, 2008;
359(1):
31 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Verweij and M. de Jonge
Multitarget Tyrosine Kinase Inhibition: [And the Winner Is...]
J. Clin. Oncol.,
June 10, 2007;
25(17):
2340 - 2342.
[Full Text]
[PDF]
|
 |
|
|